TVTX Travere Therapeutics, Inc. Common Stock

XNAS 49.60 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TVTX $49.60 —
Key stats
$49.60
52-Week Range
$22.59 – $68.73
YTD
+25.51%
IV Rank (30D)
55.76
Straddle Price
$7.40
P/C Vol Ratio
0.89
Market Cap
$5.0B
Open
$52.56
Day Range
$49.46 – $52.56
Volume
1,827,921
Prev Close
$52.79
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.21%
Beta vs SPY1.08
Cost of Equity (CAPM)11.18% (VRP-adj)
WACC10.58%
Volatility Risk Premium+25.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+2.9%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.1B
Return on Equity (TTM)-177.2%
Book / Price0.5%
Gross Margin (TTM)98.6%
FCF Margin (TTM)15.6%
Debt / Equity24.58
Quality Score2/6 — normal (10y DCF)
SMA 50$61.63 (Market Anchor value)
SMA 20 / Bollinger Mid$57.06
Bollinger Width / SMA2046.4% (drives anchor stability)
Net Debt$0.5B
Market Cap$5B
Peers used for multiples: COGT, CORT, DNTH, GH, MIRM, NKTR, SYRE, UTHR
60-Day Conviction
51%
20-Day Fair Value
≈ by Nov 16, 2026
$49.47
α -0.3% rank 11%
conviction
16%
40-Day Fair Value
≈ by Dec 15, 2026
$49.40
α -0.4% rank 11%
conviction
12%
60-Day Fair Value
≈ by Jan 13, 2027
$48.94
α -1.3% rank 11%
conviction
51%
MethodImplied PriceWeightDetail
DCF $7.55 37%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $1.34 15% median 5.1× · 6 peers
Peer P/S $108.41 15% median 16.8× · 6 peers
Market Anchor (SMA50) $61.63 0% stability 0% (BB-width)
Options Expected (B-L 30d) $52.24 34% 18 strikes · skew +0.07
As of 2026-10-16 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$5.0B
Employees
497
List Date
2003-07-23
CIK
0001438533
Next Earnings
2026-10-29 (After-Close)
EPS Forecast
$0.05 (4 est.)
Headquarters
San Diego, CA
Homepage
https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a defi…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-6.48%-10.13%8.42%-6.59%7.85%-21.33%-4.71%
Feb19.09%2.79%0.32%-12.09%5.84%-9.99%0.99%
Mar-18.29%-3.23%3.45%-2.03%-9.49%0.61%-4.83%
Apr-3.96%-9.73%-4.18%-24.35%19.32%34.05%1.86%
May-38.78%-9.41%-20.88%23.67%-27.65%6.94%-11.02%
Jun0.90%7.21%-15.60%6.48%-4.64%26.13%3.41%
Jul-11.80%-6.18%10.55%15.22%5.03%-1.22%1.93%
Aug53.09%16.80%-14.59%2.49%11.96%20.55%15.05%
Sep9.58%-12.19%-39.88%45.73%31.68%-10.39%4.09%
Oct15.15%-14.71%-23.04%25.09%41.83%-12.75%*5.26%
Nov-3.55%-9.93%-6.55%7.06%2.55%---2.08%
Dec10.90%7.63%40.03%-10.99%8.58%--11.23%
Total-1.61%-37.65%-58.84%64.40%107.99%19.93%15.70%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $56.40
SMA 50: $61.37
SMA 200: $45.82
Current: $49.60
EMA 12: $53.82
EMA 26: $56.84
MACD: -3.0261 | Signal: -0.4909
BEARISH
ADX (14): 32.72
TREND
+DI: 15.95
−DI: 31.40

Momentum Oscillators

RSI (14): 26.59
OVERSOLD
Stoch %K: 10.86
Stoch %D: 10.62
Williams %R: -98.87

Volume & Volatility

BB Upper: $64.13
BB Lower: $48.66
NEUTRAL
OBV: -9,169,779
Vol SMA 20: 1,941,682
Vol ROC: 4.87%
ATR: $2.42
True Range: $3.33
HV 20: 39.5%
HV 30: 38.7%
HV 60: 42.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-18T00:00:00 – 2026-10-16T00:00:00
AI Analysis

TVTX (Travere Therapeutics) - Comprehensive Stock Analysis

Executive Summary

Overall Assessment: BEARISH | Confidence Level: 7/10

Travere Therapeutics is experiencing significant technical deterioration coupled with mounting legal headwinds. The stock has broken below its 50-day moving average and is trading near multi-week lows with deeply oversold momentum indicators, yet this appears driven by fundamental concerns rather than presenting a classic oversold bounce opportunity. Recent litigation alerts from multiple law firms (January 31, July 17) suggest material investor concerns that are likely weighing on institutional positioning.

Key Drivers:

  • Severe technical breakdown with price 15.5% below 50-day MA ($61.89)
  • Multiple shareholder litigation investigations signaling governance or disclosure concerns
  • Deteriorating volume and negative on-balance volume indicating distribution

Primary Risks:

  • Litigation outcome uncertainty could trigger further downside or stabilization
  • High beta (1.37) means downside in bearish markets will be amplified
  • Volume collapse (-82.38% rate of change) suggests institutional exit

Investment Thesis: TVTX is in a structural downtrend with oversold technicals that lack bullish confirmation. While RSI at 28.61 suggests potential mean-reversion, the confluence of technical breakdown, negative news catalysts, and low volume conviction indicates this is likely a "falling knife" scenario rather than a capitulation bottom. The litigation alerts represent the primary near-term risk driver.

Recent News Sentiment Impact: NEGATIVE (60% of recent headlines). The July 17 law firm solicitations are the most recent major catalyst, suggesting the litigation narrative remains active. News predates the most severe price decline, indicating ongoing stock weakness despite the headlines.

Technical Analysis

Trend Direction

Short-term (1-4 weeks): BEARISH

  • Price at $52.30 is 15.5% below the 50-day SMA ($61.89)
  • Trading below both the 20-day EMA ($55.28) and 50-day SMA
  • ADX at 34.20 indicates a strong downtrend in effect (ADX >25 = strong trend)
  • -DI at 29.02 vs +DI at 11.33 shows sellers in clear control
  • Breakdown structure: Recent price action suggests lower-low formation

Medium-term (1-3 months): BEARISH

  • Price remains below the 50-day and 200-day moving averages
  • 50-day SMA ($61.89) now acting as resistance
  • No signs of trend reversal structure forming
  • Declining momentum through recent weeks based on price positioning

Long-term (3-12 months): NEUTRAL-TO-BEARISH

  • Price above 200-day SMA ($45.62) provides some longer-term support
  • But price at only 14.5% above this level leaves limited cushion
  • Lack of higher lows suggests no structural recovery pattern established

Support/Resistance Levels

Resistance (Descending Order):

  1. $58.19 (20-day SMA / MACD signal line) - Near-term resistance, currently ~11% above current price
  2. $61.89 (50-day SMA) - Significant resistance, 18% above current price
  3. $66.21 (Bollinger Bands upper band) - Would require reversal signal to approach

Support (Critical Levels):

  1. $50.17 (Bollinger Bands lower band) - Immediate support, 4% below current price
  2. $45.62 (200-day SMA) - Major structural support, 13% below current price
  3. $40-42 range (No technical levels identified, but psychological support zone)

Data Quality Note: Support/resistance levels are clearly defined by moving averages and Bollinger Bands, providing good technical framework.

Momentum Signals

RSI (14): 28.61 - OVERSOLD with Caution

  • Technically oversold (<30), typically suggesting potential reversal opportunity
  • CRITICAL CAVEAT: Oversold RSI in deteriorating trends often precedes further breakdown rather than bounces
  • RSI has room to decline further; no divergence signals present
  • Interpretation: Oversold condition may be warranted given fundamental concerns

MACD: -2.91 / Signal: -0.75 / Histogram: -2.15 - BEARISH

  • MACD below signal line (−2.91 vs −0.75) = bearish crossover in effect
  • Histogram at −2.15 shows distance between MACD and signal line is increasing
  • No bullish reversal signal present: MACD would need to cross above signal line to confirm reversal
  • Momentum remains deteriorating

Stochastic Oscillators: DEEPLY OVERSOLD

  • Stochastic %K at 6.78 (extremely oversold)
  • Stochastic %D at 5.46 (also deeply oversold)
  • Williams %R at −91.28 (extreme oversold)
  • These readings suggest potential mean reversion, but in context of strong downtrend, may indicate capitulation is incomplete

Bollinger Bands: NEUTRAL with Downside Bias

  • Price at $52.30 sits between lower band ($50.17) and middle band ($58.19)
  • Not at extreme levels; width of 27.57 is moderate, not indicating squeeze or extreme expansion
  • Position in lower half of bands suggests downside pressure persists
  • Mean reversion scenario: Could move toward middle band ($58.19), ~11% upside

Volume Analysis

Critical Red Flag - Severe Volume Deterioration:

  • Volume Rate of Change: -82.38% - Dramatic collapse in trading volume

    • This is one of the most concerning signals in the dataset
    • Suggests institutional investors have largely exited or reduced exposure
    • Low volume on down moves typically reinforces downtrend conviction

  • Volume SMA 20: 1,870,650 - Baseline average volume

    • Current volume well below this level (implied by -82% ROC)
    • Indicates disengagement from the stock

  • On-Balance Volume (OBV): -3,397,700 (negative) - BEARISH

    • Negative OBV accumulation shows distribution outweighing accumulation
    • Institutional selling has dominated recent action
    • No bullish divergence present

Volume Interpretation: The -82% volume decline combined with negative OBV and price deterioration creates a "distribution on decline" pattern—the most bearish scenario. This is NOT a healthy accumulation bottom.

News & Sentiment Analysis

Recent Headlines Summary

Litigation Theme (60% of recent headlines - PRIMARY CONCERN):

  1. July 17, 2026 - Kuehn Law: "Encourages Investors of Travere Therapeutics to Contact Law Firm" [NEGATIVE]

    • Most recent headline; vague language typical of shareholder investigation solicitations
    • Suggests unresolved investor concerns or potential class action activity

  2. January 31, 2026 - Robbins Geller Rudman & Dowd LLP: "Investigation Launched into Travere Therapeutics Inc." [NEGATIVE]

    • Formal investigation announcement; predates current price weakness by ~6 months
    • Indicates potential disclosure violations, earnings issues, or management malfeasance

  3. January 13, 2026 - RGRD Law: "Investigation Launched into Travere Therapeutics Inc." [NEGATIVE]

    • Earlier investigation notice; suggests concerns emerged in late 2025

  4. May 10, 2026 - The Motley Fool: "A Director Cashes In Near the Top, but What Remains Matters" [NEUTRAL]

    • Director stock sale near peak prices; potential timing concern but framed neutrally
    • Suggests insider selling at higher prices, value destruction for shareholders

  5. February 27, 2026 - American Kidney Fund: "Your Kidneys Count...Protect Your Health" [POSITIVE]

    • Generic kidney health awareness (unrelated to TVTX fundamentals)
    • Likely only positive by sentiment classification; not material catalyst

Sentiment Assessment

Aggregate Sentiment: NEGATIVE (60% negative, 20% neutral, 20% positive)

Critical Analysis: The sentiment breakdown is heavily skewed toward litigation-related negativity. The four most recent material headlines (Jan 13, Jan 31, May 10, July 17) all carry negative or neutral undertones, with the January investigations being the fundamental concern. The July 17 headline timing is particularly notable—it's recent

Generated
Earnings History
20 of 23 under expected move
Avg Expected Move
14.96%
Avg Actual Move
5.64%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-11 After-Close 21.42% 1.07% 0.05x Within
2021-03-01 After-Close 11.58% 4.48% 0.39x Within
2021-05-06 After-Close 10.21% 14.85% 1.45x Exceeded
2021-07-29 After-Close 34.90% 0.65% 0.02x Within
2021-10-28 After-Close 7.86% 8.35% 1.06x Exceeded
2022-01-10 After-Close 4.35% 1.32% 0.30x Within
2022-08-04 After-Close 14.35% 7.91% 0.55x Within
2023-01-09 After-Close 5.09% 3.82% 0.75x Within
2023-02-23 After-Close 10.28% 1.92% 0.19x Within
2023-05-04 After-Close 12.21% 5.20% 0.43x Within
2023-08-03 After-Close 14.25% 4.67% 0.33x Within
2023-11-07 After-Close 19.22% 11.84% 0.62x Within
2024-01-08 After-Close 17.82% 0.20% 0.01x Within
2024-05-06 After-Close 22.14% 3.05% 0.14x Within
2024-08-01 After-Close 18.94% 2.60% 0.14x Within
2024-10-31 After-Close 11.57% 0.40% 0.03x Within
2025-01-13 After-Close 8.74% 8.18% 0.94x Within
2025-05-01 After-Close 15.66% 1.88% 0.12x Within
2025-08-06 After-Close 9.86% 1.91% 0.19x Within
2025-10-30 After-Close 13.15% 18.58% 1.41x Exceeded
2026-01-12 After-Close 37.39% 14.63% 0.39x Within
2026-05-04 After-Close 7.40% 0.24% 0.03x Within
2026-08-04 After-Close 15.62% 12.03% 0.77x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TVTX Options Activity & IV Rank

TVTX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 59.2%
7-DTE IV: —
Expected Move: $7.40
7-DTE Move: $0.97
Days to Exp: 35 (2026-11-20)

Options Flow

Call Volume: 205
Put Volume: 182
P/C Volume: 0.888
NEUTRAL
Call OI: 361
Put OI: 267
P/C OI: 0.74
Total OI: 628

ATM Options Pricing

ATM Call: $3.65
ATM Put: $3.75
Call %: 7.4%
Put %: 7.6%

Chain Summary

Chain Volume: 3,755
Chain OI: 29,842
Last Updated: 10/16/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 83rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
83%
vs own history
GEX tilt
+0.51
OI-weighted, today
Vanna tilt
+0.69
δ-sensitivity to IV
Charm tilt
-0.66
δ-decay vs time
Vanna tilt +0.69: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.66: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 21 ATM contracts, 11k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 60.1% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)55.8MediumOct 16
Straddle Price (30 DTE)$7.40Oct 16
Beta Analysis

Risk Metrics

Beta: 1.3811
Alpha: 57.74%
Correlation: 0.2699
R-Squared: 7.3%
Stock Volatility: 65.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own TVTX
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$104.1M
0.14%
#146 of 3138-6.8%13F
Point72 Hedge fund
Steve Cohen
$27.2M
0.04%
#491 of 1945new13F
Citadel Hedge fund
Ken Griffin
$16.0M
0.01%
#1283 of 6285+9083.6%13F
Millennium Management Hedge fund
Izzy Englander
$10.4M
0.01%
#1548 of 3716new13F
Rockefeller Capital Management Family office
Rockefeller family
$450K
0.00%
#2137 of 4729-2.2%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TVTX Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 94,294,662 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

355 filers708,409,373 shares$7.29B value751.27% of float
# Filer Shares Value % of Total % of Float Period
1 Jupiter Topco LLC 11,324,191 $643.30M 8.82% 12.01% 2026-06-30
2 BlackRock, Inc. Custodian 58,745,663 $515.26M 7.06% 62.30% 2026-06-30
3 FMR LLC Custodian 10,268,614 $407.87M 5.59% 10.89% 2026-06-30
4 Janus Henderson Group plc 16,198,586 $345.28M 4.73% 17.18% 2026-03-31
5 Bank of America Corp Custodian 4,568,341 $259.53M 3.56% 4.84% 2026-06-30
6 State Street Corp 16,956,224 $256.71M 3.52% 17.98% 2026-06-30
7 Vanguard Group Inc Custodian 6,309,229 $241.08M 3.31% 6.69% 2025-12-31
8 Vanguard Capital Management LLC 4,108,694 $233.41M 3.20% 4.36% 2026-06-30
9 PERCEPTIVE ADVISORS LLC 3,752,574 $213.18M 2.92% 3.98% 2026-06-30
10 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 3,512,514 $160.60M 2.20% 3.73% 2026-06-30
11 ADAGE CAPITAL PARTNERS GP, L.L.C. 2,569,356 $145.97M 2.00% 2.72% 2026-06-30
12 Geode Capital Management, LLC Custodian 2,371,887 $134.77M 1.85% 2.52% 2026-06-30
13 VOYA INVESTMENT MANAGEMENT LLC 98,389,366 $127.22M 1.74% 104.34% 2026-06-30
14 TENOR CAPITAL MANAGEMENT Co., L.P. 77,733,000 $125.58M 1.72% 82.44% 2026-06-30
15 Rock Springs Capital Management LP 2,179,069 $123.79M 1.70% 2.31% 2026-06-30
16 Kynam Capital Management, LP 2,000,000 $113.62M 1.56% 2.12% 2026-06-30
17 Stephens Investment Management Group LLC 1,875,304 $106.54M 1.46% 1.99% 2026-06-30
18 RENAISSANCE TECHNOLOGIES LLC 1,833,079 $104.14M 1.43% 1.94% 2026-06-30
19 EMERALD ADVISERS, LLC 1,600,886 $90.95M 1.25% 1.70% 2026-06-30
20 Goldman Sachs Group Inc Custodian 3,308,321 $90.50M 1.24% 3.51% 2026-06-30
21 Two Sigma Investments, LP Custodian 2,065,656 $89.53M 1.23% 2.19% 2026-06-30
22 D. E. Shaw & Co., Inc. Custodian 7,940,469 $89.48M 1.23% 8.42% 2026-06-30
23 ARMISTICE CAPITAL, LLC 1,572,539 $89.34M 1.22% 1.67% 2026-06-30
24 Vanguard Portfolio Management LLC 1,541,617 $87.58M 1.20% 1.63% 2026-06-30
25 Wellington Management Group LLP Custodian 1,533,080 $87.09M 1.19% 1.63% 2026-06-30
12 filers$78.04M notional
# Filer Notional Value % of Total Period
1 ARMISTICE CAPITAL, LLC $28.41M 36.40% 2026-06-30
2 Susquehanna International Group, LLP Custodian $21.57M 27.63% 2026-06-30
3 Caption Management, LLC $10.29M 13.18% 2026-06-30
4 Jane Street Group, LLC Custodian $6.04M 7.75% 2026-06-30
5 Citadel Advisors LLC Custodian $5.86M 7.51% 2026-06-30
6 IMC-Chicago, LLC Custodian $2.15M 2.75% 2026-06-30
7 Simplex Trading, LLC Custodian $1.72M 2.20% 2026-06-30
8 GROUP ONE TRADING LLC Custodian $994.17K 1.27% 2026-06-30
9 Squarepoint Ops LLC $636.27K 0.82% 2026-06-30
10 Wolverine Trading, LLC Custodian $254.82K 0.33% 2025-09-30
11 Walleye Trading LLC $113.62K 0.15% 2026-06-30
12 JPMorgan Chase & Co Custodian $11.66K 0.01% 2026-06-30
9 filers$49.41M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $21.85M 44.23% 2026-06-30
2 Jane Street Group, LLC Custodian $17.33M 35.08% 2026-06-30
3 Citadel Advisors LLC Custodian $5.24M 10.60% 2026-06-30
4 IMC-Chicago, LLC Custodian $1.94M 3.92% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $1.56M 3.16% 2026-06-30
6 Simplex Trading, LLC Custodian $1.10M 2.22% 2026-06-30
7 TUDOR INVESTMENT CORP ET AL $329.50K 0.67% 2026-06-30
8 Walleye Trading LLC $51.13K 0.10% 2026-06-30
9 JPMorgan Chase & Co Custodian $11.66K 0.02% 2026-06-30

TVTX Insider Trading (Form 4)

Latest: 2026-09-17
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-17 Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER Mixed — $43.26 -$205.0K EDGAR
2026-09-17 Elizabeth E Reed Chief Legal Officer and GC Mixed — $38.90 -$1.76M EDGAR
2026-09-17 Jula Inrig EVP, Head of R&D & CMO Mixed −12,279 $39.89 -$2.50M EDGAR
2026-09-17 Peter Heerma EVP, CHIEF COMMERCIAL OFFICER Mixed −25,000 $40.47 -$13.81M EDGAR
2026-09-17 Christopher R. Cline CHIEF FINANCIAL OFFICER Mixed −30,508 $49.60 -$2.80M EDGAR
2026-09-17 William E. Rote Chief Research Officer Mixed −17,548 $43.03 -$9.04M EDGAR
2026-09-17 Eric M Dube CHIEF EXECUTIVE OFFICER Mixed — $43.41 -$16.05M EDGAR
2026-09-11 Jeffrey A Meckler Director Mixed — $44.64 -$906.5K EDGAR
2026-09-03 Christopher R. Cline CHIEF FINANCIAL OFFICER Sell (S) −642 $66.37 -$42.6K EDGAR
2026-08-19 Gary A Lyons Director Mixed — $40.36 -$458.4K EDGAR
2026-06-22 Jula Inrig CHIEF MEDICAL OFFICER Gift (G) −468 — EDGAR
2026-06-16 Timothy Coughlin Director Mixed — $38.30 -$235.5K EDGAR
2026-06-16 Roy D. Baynes Director Mixed — $35.69 -$128.8K EDGAR
2026-05-21 John A Orwin Director Award (A) +4,000 — EDGAR
2026-05-21 Gary A Lyons Director Award (A) +4,000 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TVTX Insider Holdings

16 insiders · @ $49.60
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Eric M Dube CHIEF EXECUTIVE OFFICER 465,054 $23.07M -$46.31M 32 2026-09-17
2 Peter Heerma EVP, CHIEF COMMERCIAL OFFICER 289,783 $14.37M -$19.81M 27 2026-09-17
3 Christopher R. Cline CHIEF FINANCIAL OFFICER 138,016 $6.85M -$4.96M 24 2026-09-17
4 Elizabeth E Reed Chief Legal Officer and GC 105,689 $5.24M -$8.76M 33 2026-09-17
5 Jeffrey A Meckler Director 101,500 $5.03M -$2.27M 9 2026-09-11
6 Jula Inrig EVP, Head of R&D & CMO 100,891 $5.00M -$5.51M 20 2026-09-17
7 William E. Rote Chief Research Officer 98,547 $4.89M -$17.79M 29 2026-09-17
8 Timothy Coughlin Director 66,250 $3.29M -$1.27M 9 2026-06-16
9 Gary A Lyons Director 62,400 $3.10M -$1.55M 9 2026-08-19
10 Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER 44,853 $2.22M -$6.30M 20 2026-09-17
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TVTX Proposed Insider Sales (Form 144)

Latest: 2026-10-15
Last 30d: 6 filings · $50.5M notice value  ·  Last 90d: 16 filings · $81.0M notice value · 9 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: ERIC DUBE (4, $38.4M) · PETER HEERMA (3, $18.0M) · WILLIAM ROTE (2, $13.4M) · CHRISTOPHER CLINE (1, $3.3M) · JULA INRIG (1, $2.9M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-15 ERIC DUBE Director, Officer 243,735 $12.98M 2026-10-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-17 ERIC DUBE Director, Officer 108,493 $6.89M 2026-09-17 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-17 PETER HEERMA Officer 8,282 $525.7K 2026-09-17 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-16 WILLIAM ROTE Officer 112,850 $7.05M 2026-09-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-16 PETER HEERMA Officer 172,717 $10.80M 2026-09-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-16 ERIC DUBE Director, Officer 195,841 $12.24M 2026-09-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 SANDRA CALVIN Officer 5,375 $353.6K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 CHRISTOPHER CLINE Officer 50,508 $3.32M 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 ELIZABETH REED Officer 39,576 $2.60M 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 ERIC DUBE Director, Officer 95,666 $6.29M 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
92 ETFs hold TVTX
25 shown · $844.90M total exposure · 0.16% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $174.4M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.16% $127.2M $78.9B 2026-10-14
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 1.24% $125.0M $10.1B 2026-10-14
4 VXF Vanguard Extended Market ETF Vanguard 0.07% $62.5M — 2026-09-30
5 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.04% $62.4M — 2026-09-30
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.33% $44.1M $13.6B 2026-10-14
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.35% $37.3M $10.7B 2026-10-14
8 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.08% $34.8M — 2026-09-30
9 VTWO Vanguard Russell 2000 ETF Vanguard 0.17% $30.6M — 2026-09-30
10 SCHA Schwab U.S. Small-Cap ETF Nport 0.09% $20.3M — 2026-05-31
11 FELG Fidelity Enhanced Large Cap Growth ETF Fidelity 0.31% $17.6M $5.7B 2026-10-14
12 VHT Vanguard Health Care ETF Vanguard 0.07% $15.1M — 2026-09-30
13 PJP Invesco Pharmaceuticals ETF Invesco 2.54% $14.0M — 2026-10-14
14 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.21% $13.4M $6.5B 2026-10-14
15 LFSC F/m Emerald Life Sciences Innovation ETF Nport 7.67% $8.1M — 2026-05-31
16 FMDE Fidelity Enhanced Mid Cap Core ETF Fidelity 0.09% $7.9M $8.3B 2026-10-14
17 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $6.6M $97.1B 2026-10-14
18 FELC Fidelity Enhanced Large Cap Core ETF Fidelity 0.07% $6.1M $8.8B 2026-10-14
19 FBCG Fidelity Blue Chip Growth ETF Nport 0.09% $5.9M — 2026-07-31
20 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.34% $5.7M — 2026-09-30
21 DFAS Dimensional US Small Cap ETF Dimensional 0.02% $5.6M — 2026-10-14
22 DFMC Dimensional US Micro Cap ETF Dimensional 0.07% $5.4M — 2026-10-14
23 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.94% $5.3M — 2026-10-15
24 PTH Invesco Dorsey Wright Healthcare Momentum ETF Nport 2.16% $5.1M — 2026-07-31
25 SBIO ALPS Medical Breakthroughs ETF Nport 2.77% $4.5M — 2026-05-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.46
TTM Revenue
$591.33M
TTM Net Income
$-43.46M
TTM Op. Cash Flow
$92.70M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$169.58M$-34.80M$-0.37$58.07M
Q1 '262026-03-31$127.20M$-37.10M$-0.40$-40.37M
Q4 '252025-12-31$129.69M$2.73M$0.03$60.68M
Q3 '252025-09-30$164.86M$25.71M$0.28$14.32M
Q2 '252025-06-30$114.45M$-12.76M$-0.14$4.98M
Q1 '252025-03-31$81.73M$-41.23M$-0.47$-42.19M
Q4 '242024-12-31$74.79M$-60.26M$-0.71$-35.72M
Q3 '242024-09-30$62.90M$-54.81M$-0.70$-42.51M
Q2 '242024-06-30$54.12M$-70.41M$-0.91$-40.24M
Q1 '242024-03-31$41.37M$-136.06M$-1.76$-119.00M
Q4 '232023-12-31$45.06M$-90.17M$-1.21$-70.47M
Q3 '232023-09-30$37.09M$150.74M$1.97$-59.13M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
190.73
P/S
7.91
EV/EBITDA
225.29
EV/Sales
8.73
ROE
-177.2%
ROA
-5.4%
Div Yield
0.00%
FCF Yield
1.98%
Debt/Equity
24.58
Current Ratio
—
Market Cap
$4.68B
as of 2026-10-16
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
12.66M
SI % of Float
14.04%
Days to Cover
7.23
Short Vol Ratio
50.2%
Free Float
90.15M
Float %
95.6%
Short interest 2026-09-30 • Short volume 2026-10-16 • Float 2026-08-24